Clinical Trials | Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

The University of Virginia is looking for adults with advanced metastatic or locally recurrent breast cancer to take part in a clinical trial. You may be eligible for this study if you have locally recurrent unresectable and/or metastatic breast cancer and have not had successful prior treatment. The goal of this study is to find out whether an investigational medication called Bria-IMT, given alone or together with a Checkpoint Inhibitor (CPI), may help treat your breast cancer. If you take part, you will be randomized (assigned by chance) to one of several study groups. These groups may include: • Bria-IMT alone, • Bria-IMT combined with the CPI, or • A treatment option chosen by you and your doctor This study will include: blood draws, electrocardiograms (ECGs), imaging assessments, questionnaires, and physical examinations. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. More information can be found here: https://clinicaltrials.gov/study/NCT06072612